guest ::
| Home > Publications database > Pivotal Phase 3 Theranostic Trials: Future Indications. |
| Home > Publications database > Pivotal Phase 3 Theranostic Trials: Future Indications. |
| Journal Article (Review Article) | DKFZ-2026-02243 |
; ; ; ;
2026
Soc.
New York, NY
Abstract: There are several ongoing phase 3 randomized trials involving radiopharmaceutical therapies (RPTs), which are expected to provide practice-changing evidence in the coming years. This review covers ongoing pivotal phase 3 trials designed to expand applications for RPTs. Trials such as PSMAcTION, STAMPEDE2, PSMA-DC, and PSMAddition focus on prostate-specific membrane antigen-directed treatments for patients with prostate cancer. NETTER-3, ACTION-1, and COMPOSE evaluate somatostatin receptor-targeted radiopharmaceuticals in individuals with neuroendocrine neoplasms. Expansion of phase 3 registration trials has been driven by increased industry investment. Ongoing RPT phase 3 trials serve as hybrids, merging nuclear medicine procedures for imaging and drug application with oncology-driven standards of care and endpoint definitions. Despite the challenges associated with this integration, phase 3 RPT trials present an opportunity to revolutionize future cancer care by introducing and expanding the use of image-guided RPT.
Keyword(s): Humans (MeSH) ; Clinical Trials, Phase III as Topic (MeSH) ; Radiopharmaceuticals: therapeutic use (MeSH) ; Theranostic Nanomedicine: methods (MeSH) ; Male (MeSH) ; Neuroendocrine Tumors: radiotherapy (MeSH) ; Prostatic Neoplasms: radiotherapy (MeSH) ; clinical trial ; phase 3 ; prospective ; theranostic ; Radiopharmaceuticals
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
